You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 140 No. 5, May 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (22)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders, Other
 •Alert me on articles by topic

Elevated Serum Granulocyte Colony-Stimulating Factor Levels in Patients With Active Phase of Sweet Syndrome and Patients With Active Behçet Disease

Implication in Neutrophil Apoptosis Dysfunction

Tamihiro Kawakami, MD, PhD; Syuichiro Ohashi, MD, PhD; Yoko Kawa, PhD; Hideto Takahama, MD, PhD; Masaru Ito, MD, PhD; Yoshinao Soma, MD, PhD; Masako Mizoguchi, MD, PhD

Arch Dermatol. 2004;140:570-574.

Background  Sweet syndrome (SS), an acute inflammatory disease, has clinical and laboratory features similar to those of Behçet disease (BD). Serum levels of granulocyte colony-stimulating factor (G-CSF) are elevated in patients with SS, and exogenous administration of G-CSF has repeatedly been implicated in the causation of SS. Granulocyte colony-stimulating factor is a hematopoietic growth factor that regulates the production and differentiation of neutrophils.

Objectives  To clarify the role of elevated serum G-CSF levels in patients with active SS and active BD compared with those with inactive SS or BD and healthy controls. To then analyze neutrophil apoptosis in the active state of SS and BD; and to also investigate the influence of autologous serum on neutrophil apoptosis.

Methods  Serum G-CSF was examined in 5 patients with active SS, 7 with inactive SS, 7 with active BD, 9 with inactive BD, and 5 healthy controls by means of an enzyme immunoassay kit. We measured apoptotic cells in the neutrophil fraction of peripheral blood collections in patients with active diseases and controls by means of flow cytometry.

Results  Serum G-CSF level was significantly higher in patients with active SS than in those with inactive SS. The difference in serum G-CSF levels among patients with active and inactive BD was also significant. Serum G-CSF level was significantly higher in patients with active SS than in those with active BD. Neutrophil apoptosis was significantly higher in patients with active SS than healthy controls. This increased apoptosis rate was also seen in patients with active BD. The increased rate of neutrophil apoptosis was significantly suppressed when the neutrophils were cultured for 18 hours in the presence of autologous active SS serum. Similarly, neutrophil apoptosis was suppressed in the presence of autologous serum in patients with active BD, but not significantly so.

Conclusions  These findings indicate that increased production of G-CSF in patients with SS and BD may play an important role in the manifestation of these disorders. Given the suppression of neutrophil apoptosis in the active state in the presence of the influence of autologous serum, which includes elevated G-CSF level, we propose that serum G-CSF plays a significant role in the suppression of neutrophil apoptosis. Furthermore, G-CSF–induced suppression of neutrophil apoptosis appears to be deeply involved in the pathogenesis of SS and BD.


From the Department of Dermatology, St Marianna University School of Medicine, Kanagawa, Japan. The authors have no relevant financial interest in this article.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Karyotypic Analysis of Bone Marrow Cells in Pyodermic Lesions Associated With Myelodysplastic Syndrome
Hamada et al.
Arch Dermatol 2008;144:643-648.
ABSTRACT | FULL TEXT  

Drug-Induced Sweet's Syndrome
Thompson and Montarella
The Annals of Pharmacotherapy 2007;41:802-811.
ABSTRACT | FULL TEXT  

Histiocytoid Sweet Syndrome: A Dermal Infiltration of Immature Neutrophilic Granulocytes
Requena et al.
Arch Dermatol 2005;141:834-842.
ABSTRACT | FULL TEXT  

Sweet Syndrome: A Disease in Histologic Evolution?
Malone and Slone
Arch Dermatol 2005;141:893-895.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.